Cargando…
A review of studies on gut microbiota and levodopa metabolism
Parkinson’s disease (PD) is the second most common neurodegenerative disease globally. Levodopa (L-dopa) has been the cornerstone for treating Parkinson’s since the 1960s. However, complications such as “wearing-off” and dyskinesia inevitably appear with disease progression. With the further develop...
Autores principales: | Zhong, Zhe, Ye, Min, Yan, Fuling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272754/ https://www.ncbi.nlm.nih.gov/pubmed/37332996 http://dx.doi.org/10.3389/fneur.2023.1046910 |
Ejemplares similares
-
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021) -
Relationship Between Gut Bacteria and Levodopa Metabolism
por: Xu, Kaifei, et al.
Publicado: (2023) -
Use of Levodopa After a Stroke: A Systematic Review
por: Moncayo, Juan A, et al.
Publicado: (2022) -
Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018) -
Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
por: Aljuaid, Maram, et al.
Publicado: (2019)